Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative...

by Abdel-Razeq H
Published 2016-10-01

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer

by Abdel-Razeq H
Published 2019-05-01

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach

by Abdel-Razeq H, Ismael Y
Published 2011-06-01

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients

by Abdel-Razeq H, Mansour A
Published 2016-08-01

Current neoadjuvant treatment options for HER2 positive breast cancer

by Abdel-Razeq H, Marei L
Published 2011-08-01

Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience

by Abdel-Razeq H, Mansour A, Ismael Y
Published 2011-03-01

Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

by Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdulelah H
Published 2013-08-01

The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience

by Mansour A, Ismael Y, Abunasser M, Hammode E, Turfa R, Abdel-Razeq H
Published 2013-10-01

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives

by Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O
Published 2021-06-01

Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country

by Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D
Published 2019-11-01

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2...

by Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Al-Haj Ali B, Ibrahim M, Rimawi D
Published 2018-04-01